Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib for cGVHD After Allogeneic Stem Cell Transplantation
NCT02611063Phase 1Completed
- Start
- Jan 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fostamatinib in chronic graft-versus-host disease (cGVHD). Primary endpoint: Maximum Tolerated Dose at 60 days. Started Jan 2016; status: completed.
02
Drugs
fostamatinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02611063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611063.